Regulus - Wikipedia Regulus is the brightest object in the constellation Leo and one of the brightest stars in the night sky It has the Bayer designation designated α Leonis, which is Latinized to Alpha Leonis, and abbreviated Alpha Leo or α Leo
Regulus Therapeutics Enters into Agreement to be Acquired by . . . SAN DIEGO, April 30, 2025 PRNewswire -- Regulus Therapeutics Inc (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced that it has entered into an agreement and plan of merger with Novartis AG ("Novartis") and an indirect
Regulus Therapeutics Our pipeline programs target kidney diseases of high unmet need, including ADPKD We are targeting the underlying biology of these diseases with a novel and potentially powerful approach: MicroRNA-based therapeutics News
Novartis announces commencement of tender offer to acquire . . . Basel, May 27, 2025 - Novartis today announced that Redwood Merger Sub Inc , a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0 001 per share (the “Shares”), of Regulus Therapeutics Inc , a Delaware
Novartis grabs kidney drug developer Regulus in $1. 7bn deal Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could
Regulus Therapeutics Inc. (RGLS) Stock Price, News, Quote . . . Regulus Therapeutics Inc , a clinical-stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States
Novartis to acquire Regulus Therapeutics and farabursen, an . . . Basel, April 30, 2025 – Novartis today announced that it has entered into an agreement to acquire Regulus Therapeutics, a San Diego-based, publicly traded (Nasdaq: RGLS) clinical-stage biopharmaceutical company focused on developing microRNA therapeutics
Regulus Therapeutics Announces Positive Clinical and . . . Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate